-
1 Comment
Nevro Corp is currently in a long term downtrend where the price is trading 4.8% below its 200 day moving average.
From a valuation standpoint, the stock is 99.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 13.2.
Nevro Corp's total revenue sank by 4.1% to $110M since the same quarter in the previous year.
Its net income has increased by 48.1% to $-7M since the same quarter in the previous year.
Finally, its free cash flow grew by 161.9% to $9M since the same quarter in the previous year.
Based on the above factors, Nevro Corp gets an overall score of 3/5.
Sector | Healthcare |
---|---|
Industry | Medical Devices |
Exchange | NYSE |
CurrencyCode | USD |
ISIN | US64157F1030 |
Market Cap | 224M |
---|---|
Target Price | 7.0667 |
PE Ratio | None |
Beta | 0.82 |
Dividend Yield | None |
Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS systems. It also offers Senza HFX iQ platform that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system. In addition, the company provides HFX AdaptivAI, a pain management platform that powers the HFX iQ SCS system, as well as surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is based in Redwood City, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for NVRO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025